MA53485A - Procédés de préparation de 4-(8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl] imidazo[1,5-a]-pyrazin-1-yl)n-(pyridin-2-yl)-benzamide - Google Patents
Procédés de préparation de 4-(8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl] imidazo[1,5-a]-pyrazin-1-yl)n-(pyridin-2-yl)-benzamideInfo
- Publication number
- MA53485A MA53485A MA053485A MA53485A MA53485A MA 53485 A MA53485 A MA 53485A MA 053485 A MA053485 A MA 053485A MA 53485 A MA53485 A MA 53485A MA 53485 A MA53485 A MA 53485A
- Authority
- MA
- Morocco
- Prior art keywords
- ynoyl
- pyrazin
- imidazo
- pyrrolidin
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724228P | 2018-08-29 | 2018-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53485A true MA53485A (fr) | 2021-12-08 |
Family
ID=67928802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053485A MA53485A (fr) | 2018-08-29 | 2019-08-28 | Procédés de préparation de 4-(8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl] imidazo[1,5-a]-pyrazin-1-yl)n-(pyridin-2-yl)-benzamide |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250119664A (ko) * | 2018-08-29 | 2025-08-07 | 아세르타 파마. 비.브이. | 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정 |
| EP3947386A1 (en) * | 2019-03-27 | 2022-02-09 | Assia Chemical Industries Ltd | Solid state forms of acalabrutinib |
| DK4054582T3 (da) | 2019-11-04 | 2025-12-01 | Astrazeneca Ab | Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter |
| CR20230018A (es) | 2020-06-19 | 2023-04-11 | Acerta Pharma Bv | Formas farmacéuticas de maleato de acalabrutinib |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372694T3 (es) | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| EP2139487B1 (en) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US8362249B2 (en) | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| US8658794B2 (en) | 2010-02-08 | 2014-02-25 | Merck Sharp & Dohme B.V. | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof |
| CN103889987B (zh) * | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| MX362181B (es) | 2013-02-19 | 2019-01-08 | Ono Pharmaceutical Co | Compuesto inhibidor de cinasa del receptor de tropomiosina (trk). |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| WO2016128912A1 (en) | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor |
| IL293821A (en) | 2015-07-02 | 2022-08-01 | Acerta Pharma Bv | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide |
| WO2017077507A1 (en) * | 2015-11-06 | 2017-05-11 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
| CN107056786B (zh) | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
| ES2856248T3 (es) | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| WO2018115965A1 (en) * | 2016-12-23 | 2018-06-28 | Acerta Pharma Bv | Solid forms of imidazopyrazine compounds |
| CN106588937B (zh) | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
| US10899770B2 (en) | 2017-02-20 | 2021-01-26 | Hangzhou Solipharma Co., Ltd. | Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof |
| US10800787B2 (en) | 2017-04-20 | 2020-10-13 | Apotex Inc. | Process for the preparation of acalabrutinib |
| CN107522701B (zh) | 2017-09-01 | 2019-11-08 | 苏州富士莱医药股份有限公司 | 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法 |
| US11161851B2 (en) | 2017-11-06 | 2021-11-02 | Suzhou Pengxu Pharmatech Co. Ltd. | Processes to produce acalabrutinib |
| CN108250186B (zh) * | 2018-02-07 | 2020-01-14 | 杭州科巢生物科技有限公司 | Acalabrutinib及其中间体的合成方法 |
| WO2019239374A1 (en) | 2018-06-13 | 2019-12-19 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase |
| KR20250119664A (ko) * | 2018-08-29 | 2025-08-07 | 아세르타 파마. 비.브이. | 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
-
2019
- 2019-08-28 KR KR1020257025628A patent/KR20250119664A/ko active Pending
- 2019-08-28 BR BR112021003480-3A patent/BR112021003480A2/pt unknown
- 2019-08-28 IL IL281025A patent/IL281025B2/en unknown
- 2019-08-28 CN CN201980055726.6A patent/CN112638878B/zh active Active
- 2019-08-28 KR KR1020217008606A patent/KR102842131B1/ko active Active
- 2019-08-28 IL IL312413A patent/IL312413B2/en unknown
- 2019-08-28 EA EA202190557A patent/EA202190557A1/ru unknown
- 2019-08-28 EP EP19766195.2A patent/EP3844149A1/en active Pending
- 2019-08-28 CN CN202510979992.5A patent/CN120904205A/zh active Pending
- 2019-08-28 MA MA053485A patent/MA53485A/fr unknown
- 2019-08-28 MY MYPI2021000982A patent/MY206899A/en unknown
- 2019-08-28 CA CA3109734A patent/CA3109734A1/en active Pending
- 2019-08-28 WO PCT/EP2019/072991 patent/WO2020043787A1/en not_active Ceased
- 2019-08-28 MX MX2021002246A patent/MX2021002246A/es unknown
- 2019-08-28 JP JP2021536157A patent/JP7439095B2/ja active Active
- 2019-08-28 US US17/271,750 patent/US12024520B2/en active Active
- 2019-08-28 AU AU2019332882A patent/AU2019332882B2/en active Active
- 2019-08-28 IL IL322382A patent/IL322382A/en unknown
-
2021
- 2021-02-25 MX MX2023011692A patent/MX2023011692A/es unknown
- 2021-03-23 CO CONC2021/0003676A patent/CO2021003676A2/es unknown
-
2022
- 2022-02-09 AU AU2022200828A patent/AU2022200828B2/en active Active
-
2023
- 2023-06-20 ZA ZA2023/06381A patent/ZA202306381B/en unknown
- 2023-07-13 AU AU2023204660A patent/AU2023204660B2/en active Active
- 2023-12-18 JP JP2023212753A patent/JP7829541B2/ja active Active
-
2024
- 2024-04-10 AU AU2024202290A patent/AU2024202290A1/en not_active Abandoned
- 2024-05-09 US US18/659,338 patent/US12448387B2/en active Active
- 2024-12-09 ZA ZA2024/09391A patent/ZA202409391B/en unknown
-
2025
- 2025-09-12 US US19/326,835 patent/US20260109701A1/en active Pending
- 2025-10-21 JP JP2025176881A patent/JP2026021364A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123796T1 (el) | Στερεες μορφες μιας ενωσης που τροποποιει κινασες | |
| HUE060797T2 (hu) | Eljárás N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)- piridin-3-il)-3-metilbutánamid elõállítására | |
| DK4053128T3 (da) | 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidinderivater og relaterede forbindelser som trk-kinasehæmmere til cancerbehandling | |
| EA201990048A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ | |
| IL270134B (en) | A process for the preparation of compounds 3,2-dihydrothiazolo[2,3-a]pyrimidine-4-threat optical activity | |
| IL281025A (en) | Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| EP4252853A3 (en) | Compounds and compositions for treating hematological disorders | |
| WO2015095337A3 (en) | PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT | |
| IL282006B1 (en) | Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| EP3481827A4 (en) | IMIDAZO [1,2-A] pyridine derivatives, process for their preparation and use thereof | |
| IL204437A (en) | History of aryl cyclic profile and their use | |
| WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| ZA201000212B (en) | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treatment of inflammation | |
| ECSP077985A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
| WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| SI3357922T1 (sl) | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev | |
| MX379000B (es) | Proceso para preparar inhibidores de tirosina cinasa de bruton (btk). | |
| EA201000618A1 (ru) | 5-цианотиенопиридины для лечения опухолей | |
| SG11202103457PA (en) | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | |
| CY1122768T1 (el) | (r)-3-((3s,4s)-3-φθορο-4-(4-υδροξυφαινυλ)πιπεριδιν-1-υλ)-1-(4-μεθυλβενζυλ)πυρρολιδιν-2-ονη και προφαρμακα αυτης για τη θεραπεια ψυχιατρικων διαταραχων | |
| WO2015124934A8 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
| SI3774795T1 (sl) | 4-(1H-imidazol-5-il)-1H-pirolo (2,3-B) piridini za uporabo pri zdravljenju levkemij, limfomov in trdnih tumorjev |